Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center

• Published in: JTO clinical and research reports Vol. 1; no. 1; p. 100013
• Main Authors: Isaksson, Sofi, Hazem, Bassam, Jönsson, Mats, Reuterswärd, Christel, Karlsson, Anna, Griph, Håkan, Engleson, Jens, Oskarsdottir, Gudrun, Öhman, Ronny, Holm, Karolina, Rosengren, Frida, Annersten, Karin, Jönsson, Göran, Borg, Åke, Edsjö, Anders, Levéen, Per, Brunnström, Hans, Lindquist, Kajsa Ericson, Staaf, Johan, Planck, Maria
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2020; Elsevier
• Subjects: Chemotherapy; Driver oncogenes; Hematology, Oncology, and Palliative Medicine; Lung cancer; Massive parallel sequencing; Never smoker; Original; Chemotherapy; Massive parallel sequencing; Driver oncogenes; Never smoker; Lung cancer
• DOI: 10.1016/j.jtocrr.2020.100013
• ISSN: 2666-3643

Mutation analysis by massive parallel sequencing (MPS) is routinely performed in the clinical management of lung cancer in Sweden. We describe the clinical and mutational profiles of lung cancer patients subjected to the first 1.5 years of treatment predictive MPS testing in an autonomous regional health care region. Tumors from all patients with lung cancer who had an MPS test from January 2015 to June 2016 in the Skåne health care region in Sweden (1.3 million citizens) were included. Six hundred eleven tumors from 599 patients were profiled using targeted sequencing with a 26-gene exon-focused panel. Data on disease patterns and characteristics of the patients subjected to testing were assembled, and correlations between mutational profiles and clinical features were analyzed. MPS with the 26-gene panel revealed alterations in 92% of the 611 lung tumors, with the most frequent mutations detected in the nontargetable genes TP53 (62%) and KRAS (37%). Neither KRAS nor TP53 mutations were associated with disease pattern, chemotherapy response, progression-free survival, or overall survival in advanced-stage disease treated with platinum-based doublet chemotherapy as a first-line treatment. Among targetable genes, EGFR driver mutations were detected in 10% of the tumors, and BRAF p.V600 variants in 2.3%. For the 71 never smokers (12%), targetable alterations (EGFR mutations, BRAF p.V600, MET exon 14 skipping, or ALK/ROS1 rearrangement) were detected in 59% of the tumors. Although the increasing importance of MPS as a predictor of response to targeted therapies is indisputable, its role in prognostics or as a predictor of clinical course in nontargetable advanced stage lung cancer requires further investigation.